Application Note: Emerging drug targets in cancer immunotherapy

Cancer is the second leading cause of death globally. Immunotherapy harnesses the immune system to fight cancer cells and has emerged as the first-line therapy (standard treatment) for many solid tumors. Inspired by the great success of PD-1/PD-L1 inhibitors, researchers in industry and academia are collaborating to identify other novel target molecules, such as T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), CD47 and signal regulatory protein α (SIRPα), to maximize the efficacy of immunotherapy. Download this Application Note by Sino Biological to learn more about: Anti-TIGIT agents under clinical development CD47/SIRPα inhibitors under clinical trials High polymorphism in the...